Oscotec Inc (039200) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Oscotec Inc stock KRW 21,262, price KRW 36,300, that is 41.4% below the price, quality 77 out of 100. Rating: strongly overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range 16,150 KRW – 62,000 KRW · fair‑value band 13,075 KRW – 26,578 KRW · the 36,300 KRW price screens above the 21,262 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Oscotec in your weekly email
Every Wednesday you see whether Oscotec is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Oscotec Inc. operates as a clinical stage drug discovery and development company.
Show moreShow less
It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in preclinical Phase for the treatment of Alzheimer's disease.
The company also offers dental health products, such as bone graft comprising InduCera, BioCera-F, and SynCeraII; and membrane consisting of LysoGide and CollaGuide.
In addition, it provides functional ingredients comprises OPB for osteoporosis; AIF for arthritis; SGA that enhance bone growth; and PRF-K for perio diseases. The company was formerly known as Oscotec Co., Ltd and changed its name to Oscotec Inc. in June 1999.
Oscotec Inc. was founded in 1988 and is based in Seongnam, South Korea.
Stock analysis
Oscotec Inc (039200) currently trades at 36,300 KRW, while our model-based Fair Value estimate is 21,262 KRW, 41% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 63,569 KRW per share, and 5 of the 24 models we run sit above the 36,300 KRW price.
Bear case: the Asset-Based group reads lowest at 3,932 KRW, and 19 of the 24 models stay below the price. Data coverage for this calculation is low.
Scenario range: 13,075 KRW (bear) to 26,578 KRW (bull), the price of 36,300 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 77/100 (high quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Oscotec Inc reported revenue of 99.8B KRW in FY2025 versus 3.9B KRW in FY2021, a compound +124.9%/yr. Reported net income was 52.3B KRW in FY2025.
Key figures
Market cap 1.4T KRW (≈ $1.0B) Small · Net margin 52.4% · Return on equity 35.9% · Return on assets (EBIT) −16.8% (5-year average) · Operating margin −565% · Revenue growth (YoY) +30.5% · Free cash flow 7.5B KRW · Net debt 293M KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 92 out of 100 (low confidence).
What moves the price
The share trades about 41% below its 52-week high and 28% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −16% fair-value upside, at −41%, 039200 screens richer than that median.
Fair Value models
Bear13,075 KRWFair Value 21,262 KRWBull26,578 KRW
Price 36,300 KRW · Downside -41.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.67/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+193.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+170.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.1%
Start year 2020 (pandemic). Over 10 years: +18.5% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.1%
’13
’14
’15
’16
’17
’18
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
3.1% (2020) → 52.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+57.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +54.3% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 54 stocks
Beats the industry median on 5/8 measures
Overall it ranks above its industry peers.
Valuation
Quality Score77 · Top 25%
Fair Value upside−41.4% · Below median
Profitability
Return on equity (12 months)35.9% · Top 25%
Return on assets22.8% · Top 25%
Net margin (12 months)52.4% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)30.5% · Above median
Valuation Multiplesvs Pharmaceuticals median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Oscotec Inc Fair Value". https://www.fairvalue-calculator.com/stock/039200
Frequently asked questions
Is Oscotec Inc (039200) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of 21,262 KRW versus a price of 36,300 KRW, about 41% lower (overvalued).
What is the fair value of 039200?
Our model-based fair value for Oscotec Inc is 21,262 KRW (as of Nov 5, 2026), built from audited fundamentals. The current price: 36,300 KRW.
What is the quality score of 039200?
Oscotec Inc has a Quality Score of 77/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Oscotec Inc (039200)?
Our model-based price target is the fair value of 21,262 KRW (as of Nov 5, 2026) from 24 valuation models. Cautious scenario 13,075 KRW, optimistic scenario 26,578 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Oscotec Inc stock forecast for 2026?
Our models put fair value at 21,262 KRW, about 41% lower versus a price of 36,300 KRW (overvalued). Cautious scenario 13,075 KRW, optimistic scenario 26,578 KRW. The calculation is refreshed regularly with new filings.
What growth is priced into Oscotec Inc (039200)?
For today's price to be fair in a discounted-cash-flow model, Oscotec Inc would have to grow free cash flow by +57.5 % per year for five years (discount rate 11.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +18.1 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of 039200 use?
Our models discount Oscotec Inc at 11.0 %: a base by market capitalisation (small), damped by beta 0.77, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Oscotec Inc that is +57.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.0 %) and the same formula as our fair value.
How much growth has Oscotec Inc (039200) delivered so far?
Over the past 5 years revenue at Oscotec Inc grew +18.1 % a year. The price currently implies free-cash-flow growth of +57.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Oscotec Inc (039200) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Oscotec Inc (+57.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Oscotec Inc (039200)?
The free-cash-flow yield on the price is 0.54 %: that much free cash flow Oscotec Inc produces per unit of market value. When it exceeds the discount rate of our models (11.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Oscotec Inc (039200)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Oscotec Inc it is 21,262 KRW per share (as of Nov 5, 2026), against a price of 36,300 KRW. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Oscotec Inc stock overvalued or undervalued in 2026?
As of Nov 5, 2026, 039200 trades above its calculated fair value: price 36,300 KRW, fair value 21,262 KRW, a gap of about −41% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 039200?
No. The price is what the market pays today (36,300 KRW); the fair value is what the company's own numbers justify (21,262 KRW). For Oscotec Inc the two are 15,038 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Oscotec Inc worth?
The market values Oscotec Inc at about 1.4T KRW (market capitalisation, as of Nov 5, 2026). Per share that is 36,300 KRW; our models calculate a fair value of 21,262 KRW per share.
What do the bullish and bearish scenarios say about 039200?
Our models span a range for Oscotec Inc: cautious scenario 13,075 KRW, base 21,262 KRW, optimistic 26,578 KRW per share (as of Nov 5, 2026, price 36,300 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Oscotec Inc (039200)?
Balance-sheet figures for Oscotec Inc (as of Nov 5, 2026): return on equity 35.9%. They feed the Quality Score of 77/100, which measures business quality independently of the share price.
How far is 039200 from its 52-week high?
Oscotec Inc trades at 36,300 KRW, about 41% below its 52-week high of 62,000 KRW and 28% above the low of 28,400 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 21,262 KRW is for.
Which stocks are comparable to Oscotec Inc?
From the same area (Healthcare) we also value ST Pharm Co, Caregen Co, DongKook Pharmaceutical Co, SHUKRAPHAR, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Oscotec Inc stock attractive at the current price?
The data as of Nov 5, 2026: price 36,300 KRW, calculated fair value 21,262 KRW (−41%), Quality Score 77/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 039200 calculated?
We run Oscotec Inc through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 21,262 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Oscotec Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Oscotec Inc (039200)?
The closing price on Nov 6, 2026 was 36,300 KRW. Our model-based fair value is 21,262 KRW, about 41% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Oscotec Inc right now?
A high-quality business (quality 77/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case (26,578 KRW). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (13,075 KRW to 26,578 KRW) leaves room in how you read the outcome.
Key figures of Oscotec Inc
How large is the market capitalisation of Oscotec Inc (039200)?
The market capitalisation of Oscotec Inc is 1.4T KRW (≈ $1.0B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the net margin of Oscotec Inc (039200)?
The net margin of Oscotec Inc is 52.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Oscotec Inc (039200)?
The return on equity (ROE) of Oscotec Inc is 35.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Oscotec Inc (039200)?
On an EBIT basis the return on assets of Oscotec Inc is −16.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Oscotec Inc (039200)?
The operating margin of Oscotec Inc is −565% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Oscotec Inc (039200)?
Revenue at Oscotec Inc is growing +30.5% versus a year earlier (3y avg +170%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Oscotec Inc (039200) carry?
The net debt of Oscotec Inc is 293M KRW (fiscal year 2025, ≈ 0.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Oscotec Inc in the live analysis
One click puts Oscotec Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 5, 2026